Synonym
Pegcantratinib; CT 327; CT-327; CT327; SNA-120; SNA120; SNA 120
IUPAC/Chemical Name
3-[2-(2-methoxyethoxy)ethyl]-15'-methylspiro[1,3-oxazolidine-5,16'-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene]-2,3',4-trione
InChi Key
MTDVEOMKVDOULD-UHFFFAOYSA-N
InChi Code
InChI=1S/C32H28N4O7/c1-31-32(29(38)34(30(39)43-32)11-12-41-14-13-40-2)15-22(42-31)35-20-9-5-3-7-17(20)24-25-19(16-33-28(25)37)23-18-8-4-6-10-21(18)36(31)27(23)26(24)35/h3-10,22H,11-16H2,1-2H3,(H,33,37)
SMILES Code
O=C(N1CCOCCOC)OC2(C3(C)N4C5=CC=CC=C5C6=C7CNC(C7=C(C8=C46)C9=CC=CC=C9N8C(O3)C2)=O)C1=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
580.59
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Danilenko M, Stamp E, Stocken DD, Husain A, Zangarini M, Cranston A, Stones R, Sinclair N, Hodgson K, Bowett SA, Roblin D, Traversa S, Plummer R, Veal G, Langtry JAA, Ashworth A, Burn J, Rajan N. Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial. JAMA Dermatol. 2018 Aug 1;154(8):913-921. doi: 10.1001/jamadermatol.2018.1610. PMID: 29955768; PMCID: PMC6128505.
2: Zangarini M, Rajan N, Danilenko M, Berry P, Traversa S, Veal GJ. Development and validation of LC-MS/MS with in-source collision-induced dissociation for the quantification of pegcantratinib in human skin tumors. Bioanalysis. 2017 Feb;9(3):279-288. doi: 10.4155/bio-2016-0199. Epub 2017 Jan 23. PMID: 28111963; PMCID: PMC5292016.
3: Cranston A, Stocken DD, Stamp E, Roblin D, Hamlin J, Langtry J, Plummer R, Ashworth A, Burn J, Rajan N. Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial. Trials. 2017 Mar 7;18(1):111. doi: 10.1186/s13063-017-1812-z. PMID: 28270164; PMCID: PMC5341402.
4: Danilenko M, Hodgson K, Stones R, Husain A, Zangarini M, Veal G, Rajan N. Diverse assays from a single skin punch biopsy to assess topical drug intervention. Br J Dermatol. 2019 Apr;180(4):937-938. doi: 10.1111/bjd.17353. Epub 2019 Jan 20. PMID: 30367471; PMCID: PMC6487947.
